German Breast Group, Neu-Isenburg, Germany.
Oncol Res Treat. 2014;37(10):563-8. doi: 10.1159/000367643. Epub 2014 Sep 3.
Within 2 decades, neoadjuvant therapy (NAT) has become a standard treatment option in breast cancer. The advantage of NAT is the ability to monitor the treatment effect. Pathological complete response (pCR) after NAT is a very good predictor for long-term outcome. Clinical factors, such as age and body mass index, as well as recently identified biomarkers can predict the chance of achieving a pCR. Hormone-receptor status, proliferation markers, immune infiltrates and genetic alterations, such as germline BRCA and PIK3CA, can now be measured almost on a routine basis due to the decreased analysis costs.
在 20 年内，新辅助治疗（NAT）已成为乳腺癌的标准治疗选择。NAT 的优势在于能够监测治疗效果。NAT 后的病理完全缓解（pCR）是长期预后的一个很好的预测指标。临床因素，如年龄和体重指数，以及最近确定的生物标志物，可以预测实现 pCR 的机会。由于分析成本降低，激素受体状态、增殖标志物、免疫浸润和遗传改变，如种系 BRCA 和 PIK3CA，现在几乎可以常规测量。
